Results 61 to 70 of about 2,674,072 (303)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

On Potential Interactions between Non-selective Cation Channel TRPM4 and Sulfonylurea Receptor SUR1*

Journal of Biological Chemistry, 2012
Background: SUR1, the regulatory subunit of KATP channels, was hypothesized to associate with TRPM4 to form novel channels, implicated in cell death following neurovascular trauma.
M. Sala-Rabanal, Shizhen Wang, C. Nichols   +2 more
semanticscholar   +1 more source

Developmental and Tissue-Specific Sulfonylurea Receptor Gene Expression [PDF]

Endocrinology, 1997
We have studied the developmental regulation of mouse sulfonylurea receptor (SUR) gene expression throughout several embryonic stages as well as in the adult mouse. To this end we used a 229-bp mouse complementary DNA corresponding to the 3'-end of the SUR gene for in situ hybridization and solution hybridization/ribonuclease protection assays.
C, Hernández-Sánchez, T L, Wood, D, LeRoith   +2 more
openaire   +2 more sources

Glibenclamide–sulfonylurea receptor 1 antagonist alleviates LPS-induced BV2 cell activation through the p38/MAPK pathway

, 2017
We investigated the anti-neuroinflammatory activity and mechanism of glibenclamide, sulfonylurea receptor 1 (Sur1) antagonist, against LPS-induced microglial activationin vitro.
Fang Yuan, Jun Ding, Guoyuan Yang, Zhiming Xu, Liping Wang, Hengli Tian, Meijie Qu, Yingliang Liu, Dianxu Yang   +8 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis

Diabetes & Vascular Disease Research, 2022
While hemoglobin A1c (HbA1c) is commonly used to monitor therapy response in type 2 diabetes (T2D), GV is emerging as an essential additional metric for optimizing glycemic control.
SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim Ph.D   +4 more
doaj   +1 more source

Membrane Topology of the Amino-terminal Region of the Sulfonylurea Receptor [PDF]

Journal of Biological Chemistry, 1999
The sulfonylurea receptor (SUR) is a member of the ATP-binding cassette family that is associated with Kir 6.x to form ATP-sensitive potassium channels. SUR is involved in nucleotide regulation of the channel and is the site of pharmacological interaction with sulfonylurea drugs and potassium channel openers.
K F, Raab-Graham, L J, Cirilo, A A, Boettcher, C M, Radeke, C A, Vandenberg   +4 more
openaire   +2 more sources

Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with 99mTc-DTPA-glipizide

Annals of Nuclear Medicine, 2012
ObjectiveThis study was aimed to assess pancreas beta cell activity using 99mTc-diethyleneaminepentaacetic acid-glipizide (DTPA-GLP), a sulfonylurea receptor agent.
C. Oh, S. Kohanim, Fanlin Kong, Ho-Chun Song, N. Huynh, R. Mendez, M. Chanda, E. E. Kim, David J. Yang   +8 more
semanticscholar   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM

eLife, 2017
Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear ...
Gregory M Martin, Balamurugan Kandasamy, Frank DiMaio, Craig Yoshioka, Show-Ling Shyng   +4 more
doaj   +1 more source